128 related articles for article (PubMed ID: 30396958)
1. Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.
Heath EI; Heilbrun LK; Smith D; Schopperle WM; Ju Y; Bolton S; Ahmed Q; Sakr WA
Anticancer Res; 2018 Nov; 38(11):6361-6366. PubMed ID: 30396958
[TBL] [Abstract][Full Text] [Related]
2. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma.
Schopperle WM; DeWolf WC
Stem Cells; 2007 Mar; 25(3):723-30. PubMed ID: 17124010
[TBL] [Abstract][Full Text] [Related]
3. The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells.
Schopperle WM; Lee JM; Dewolf WC
Biochem Biophys Res Commun; 2010 Jul; 398(3):372-6. PubMed ID: 20599725
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis.
Mazzucchelli R; Barbisan F; Santinelli A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
Hum Pathol; 2011 Dec; 42(12):1931-6. PubMed ID: 21676431
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.
Barbisan F; Mazzucchelli R; Santinelli A; Lopez-Beltran A; Cheng L; Scarpelli M; Montorsi F; Montironi R
Eur Urol; 2009 Jul; 56(1):105-12. PubMed ID: 18468781
[TBL] [Abstract][Full Text] [Related]
6. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Sizemore S; Cicek M; Sizemore N; Ng KP; Casey G
Cancer Res; 2007 Jul; 67(13):6183-91. PubMed ID: 17616675
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN.
Tateno H; Matsushima A; Hiemori K; Onuma Y; Ito Y; Hasehira K; Nishimura K; Ohtaka M; Takayasu S; Nakanishi M; Ikehara Y; Nakanishi M; Ohnuma K; Chan T; Toyoda M; Akutsu H; Umezawa A; Asashima M; Hirabayashi J
Stem Cells Transl Med; 2013 Apr; 2(4):265-73. PubMed ID: 23526252
[TBL] [Abstract][Full Text] [Related]
8. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
9. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
10. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
Cao W; Li F; Yao J; Yu J
BMC Cancer; 2015 Nov; 15():915. PubMed ID: 26582057
[TBL] [Abstract][Full Text] [Related]
14. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
15. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin.
Schopperle WM; Kershaw DB; DeWolf WC
Biochem Biophys Res Commun; 2003 Jan; 300(2):285-90. PubMed ID: 12504081
[TBL] [Abstract][Full Text] [Related]
16. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
18. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer.
Dawson DM; Lawrence EG; MacLennan GT; Amini SB; Kung HJ; Robinson D; Resnick MI; Kursh ED; Pretlow TP; Pretlow TG
J Natl Cancer Inst; 1998 Apr; 90(7):519-23. PubMed ID: 9539247
[TBL] [Abstract][Full Text] [Related]
20. Podocalyxin as a major pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and induced pluripotent stem cells.
Toyoda H; Nagai Y; Kojima A; Kinoshita-Toyoda A
Glycoconj J; 2017 Dec; 34(6):817-823. PubMed ID: 28980094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
